Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib (Iressa) versus methotrexate in previously treated squamous cell carcinoma of the head and neck
2004-002662-38Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gefitinib in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by AstraZeneca. Primary endpoints: overall survival and symptom improvement. Started Nov 2004; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2004-002662-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002662-38.